Comparative Pharmacology
Head-to-head clinical analysis: GASTROMARK versus PANTOPAQUE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GASTROMARK versus PANTOPAQUE.
GASTROMARK vs PANTOPAQUE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Gastromark (ferumoxsil) is an oral superparamagnetic contrast agent used in MRI. It contains iron oxide particles that create local magnetic field inhomogeneities, reducing T2* signal in the gastrointestinal tract, thereby improving visualization of abdominal organs by darkening the bowel lumen.
Pantopaque is an iodinated oil-based contrast agent that attenuates X-rays, allowing visualization of the subarachnoid space during myelography. It acts as a positive contrast medium by increasing the absorption of X-rays in the cerebrospinal fluid.
Orally, 30-60 mL of a 1% suspension (300-600 mg iron) diluted in water or juice, given 12-24 hours prior to MRI examination; may be repeated if necessary.
Adults: 5-15 mL (6-18 g iophendylate) intrathecally for myelography via lumbar puncture. No repeated dosing.
None Documented
None Documented
Terminal elimination half-life: 3.1-3.5 hours; clinical context: supports rapid clearance from the body after imaging.
Terminal elimination half-life is approximately 6 hours in patients with normal renal function. In renal impairment, half-life is significantly prolonged (up to 24–48 hours in severe impairment), requiring dose adjustment or avoidance.
Renal: 23-31% as intact compound; fecal: 69-77% via biliary elimination; very little metabolism.
Primarily renal (glomerular filtration) with approximately 60-70% of the dose excreted unchanged in urine within 24 hours. Biliary/fecal excretion accounts for less than 5% of the administered dose; minor metabolism occurs, but the majority is eliminated unchanged via kidneys.
Category C
Category C
Radiographic Contrast Agent
Radiographic Contrast Agent